Targeted Therapies

Most new “small molecules” can be taken by mouth. Many work by blocking pathways that the cancer cells have pirated and become addicted to such as signaling pathways. Examples include ibrutinib, acalabrutinib, duvelisib and others. Others, such as venetoclax, remove blockades that the cancer has created which prevent natural cell death. These therapies target the cancer and spare most healthy cells.


Pirtobrutinib was generally well-tolerated, and most patients did not experience high-grade recurrence of the adverse event that led to discontinuation of the prior covalent Bruton tyrosine kinase inhibitor (BTKi). Pirtobrutinib may be an important option to extend the benefit of BTK inhibition among patients who could not tolerate previous
In this interview, Dr. Brian Koffman interviewed Dr. Jennifer Brown, Director of the CLL Center at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. They discussed the ALPINE trial, a phase 3 clinical trial directly comparing the efficacy of zanubrutinib vs. ibrutinib in patients with relapsed/refractory

When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.